584 related articles for article (PubMed ID: 18991165)
21. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.
Kim KM; Kim JH; Park IS; Ko GY; Yoon HK; Sung KB; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2009 May; 24(5):806-14. PubMed ID: 19207681
[TBL] [Abstract][Full Text] [Related]
22. Model for End-Stage Liver Disease (MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the Child-Turcotte-Pugh (CTP) system?
Cuomo O; Perrella A; Arenga G
Transplant Proc; 2008; 40(6):1906-9. PubMed ID: 18675085
[TBL] [Abstract][Full Text] [Related]
23. Model for End-stage Liver Disease score fails to predict perioperative outcome after hepatic resection for hepatocellular carcinoma in patients without cirrhosis.
Teh SH; Sheppard BC; Schwartz J; Orloff SL
Am J Surg; 2008 May; 195(5):697-701. PubMed ID: 18367132
[TBL] [Abstract][Full Text] [Related]
24. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
[TBL] [Abstract][Full Text] [Related]
25. Comparative study of survival of patients with hepatocellular carcinoma predicted by different staging systems using multivariate analysis.
Nanashima A; Omagari K; Tobinaga S; Shibata K; Sumida Y; Mine M; Morino S; Shibasaki S; Ide N; Shindou H; Nagayasu T
Eur J Surg Oncol; 2005 Oct; 31(8):882-90. PubMed ID: 15993031
[TBL] [Abstract][Full Text] [Related]
26. Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients?
Giannini E; Botta F; Fumagalli A; Malfatti F; Testa E; Chiarbonello B; Polegato S; Bellotti M; Milazzo S; Borgonovo G; Testa R
Liver Int; 2004 Oct; 24(5):465-70. PubMed ID: 15482344
[TBL] [Abstract][Full Text] [Related]
27. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
[TBL] [Abstract][Full Text] [Related]
28. Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis.
Lv XH; Liu HB; Wang Y; Wang BY; Song M; Sun MJ
J Gastroenterol Hepatol; 2009 Sep; 24(9):1547-53. PubMed ID: 19686416
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma.
Limquiaco JL; Wong GL; Wong VW; Lai PB; Chan HL
J Gastroenterol Hepatol; 2009 Jan; 24(1):63-9. PubMed ID: 19054256
[TBL] [Abstract][Full Text] [Related]
30. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.
Grieco A; Marcoccia S; Miele L; Marmiroli L; Caminiti G; Ragazzoni E; Cotroneo AR; Cefaro GA; Rapaccini GL; Gasbarrini G
Hepatogastroenterology; 2003; 50(49):207-12. PubMed ID: 12630024
[TBL] [Abstract][Full Text] [Related]
31. [The correlation of Child-Pugh score, PGA index and MELD score in the patient with liver cirrhosis and hepatocellular carcinoma according to the cause of alcohol and hepatitis B virus].
Mun BS; Ahn HS; Ahn DS; Lee SO
Taehan Kan Hakhoe Chi; 2003 Jun; 9(2):107-15. PubMed ID: 12824750
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of treatment methods for hepatocellular carcinoma--based on JIS score].
Kudo M; Chung H; Osaki Y; Kasugai H; Oka H; Seki T
Gan To Kagaku Ryoho; 2004 Dec; 31(13):2100-4. PubMed ID: 15628751
[TBL] [Abstract][Full Text] [Related]
33. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients.
Chen CH; Hu FC; Huang GT; Lee PH; Tsang YM; Cheng AL; Chen DS; Wang JD; Sheu JC
Eur J Cancer; 2009 Jun; 45(9):1630-9. PubMed ID: 19157858
[TBL] [Abstract][Full Text] [Related]
34. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Cho YK; Chung JW; Kim JK; Ahn YS; Kim MY; Park YO; Kim WT; Byun JH
Cancer; 2008 Jan; 112(2):352-61. PubMed ID: 18008352
[TBL] [Abstract][Full Text] [Related]
35. [Clinical value of Child-Turcotte-Pugh and model for end-stage liver disease score to predict the prognosis of chronic severe hepatitis].
Jiang ZS; Jiang JN
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Jul; 19(7):412-5. PubMed ID: 17631709
[TBL] [Abstract][Full Text] [Related]
36. Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End-stage Liver Disease score.
Angermayr B; Luca A; König F; Bertolini G; Ploner M; Gridelli B; Ulbrich G; Reiberger T; Bosch J; Peck-Radosavljevic M
Eur J Clin Invest; 2009 Jan; 39(1):65-71. PubMed ID: 19087131
[TBL] [Abstract][Full Text] [Related]
37. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score.
Huo TI; Wu JC; Lin HC; Lee FY; Hou MC; Lee PC; Chang FY; Lee SD
J Hepatol; 2005 Jun; 42(6):826-32. PubMed ID: 15885353
[TBL] [Abstract][Full Text] [Related]
39. Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study.
Yamagiwa K; Shiraki K; Yamakado K; Mizuno S; Hori T; Yagi S; Hamada T; Iida T; Nakamura I; Fujii K; Usui M; Isaji S; Ito K; Tagawa S; Takeda K; Yokoi H; Noguchi T
J Gastroenterol Hepatol; 2008 Mar; 23(3):482-90. PubMed ID: 18086115
[TBL] [Abstract][Full Text] [Related]
40. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models.
Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee PC; Loong CC; Chiang JH; Huo TI; Lee SD
Cancer; 2010 Jun; 116(12):3006-14. PubMed ID: 20564406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
